<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">35170385</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>07</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>07</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1525-6049</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>44</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Dec</Month>
            </PubDate>
          </JournalIssue>
          <Title>Renal failure</Title>
          <ISOAbbreviation>Ren Fail</ISOAbbreviation>
        </Journal>
        <ArticleTitle>MiR-122-5p promotes peritoneal fibrosis in a rat model of peritoneal dialysis by targeting Smad5 to activate Wnt/β-catenin pathway.</ArticleTitle>
        <Pagination>
          <StartPage>191</StartPage>
          <EndPage>203</EndPage>
          <MedlinePgn>191-203</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1080/0886022X.2022.2030360</ELocationID>
        <Abstract>
          <AbstractText>Peritoneal fibrosis (PF) is the main reason leading to declining efficiency and ultrafiltration failure of peritoneum, which restricts the application of peritoneal dialysis (PD). We aimed to investigate the effects and mechanisms of miR-122-5p on the PF. Sprague-Dawley (SD) rats were infused with glucose-based standard PD fluid to establish PF model. HE staining was performed to evaluate the extent of PF. Real-time fluorescence quantitative polymerase chain reaction (RT-qPCR) and fluorescence <i>in situ</i> hybridization (FISH) were performed to measure the expression level of miR-122-5p. Western blot was used to test the expression of transforming growth factor (TGF)-β1, platelet-derived growth factor (PDGF)-A, Fibronectin 1 (FN1), extracellular matrix protein 1 (ECM1), Smad5, α-smooth muscle actin (SMA), collagen type 1(COL-1), Vimentin, E-Cadherin, Wnt1, β-catenin, p-β-catenin, c-Myc, c-Jun, and Cyclin D1. Immunohistochemistry (IHC) staining was used to detect type I collagen alpha 1 (Col1α1), α-SMA, and E-Cadherin expression. We found PF was glucose concentration-dependently enhanced in peritoneum of PD rat. The PD rats showed increased miR-122-5p and decreased Smad5 expression. MiR-122-5p silencing improved PF and epithelial-mesenchymal transition (EMT) process in PD rats. MiR-122-5p silencing attenuated the activity of the Wnt/β-catenin signaling pathway. Importantly, dual-luciferase reporter assay showed Smad5 was a target gene of miR-122-5p. Smad5 overexpression significantly reversed the increases of PF and EMT progression induced by miR-122-5p overexpression. Moreover, miR-122-5p mimic activated Wnt/β-catenin activity, which was blocked by Smad5 overexpression. Overall, present results demonstrated that miR-122-5p overexpression showed a deterioration effect on PD-related PF by targeting Smad5 to activate Wnt/β-catenin pathway.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Yirong</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Nephrology, Xining No.1 People's Hospital, Xining, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ma</LastName>
            <ForeName>Zhihong</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Nephrology, Xining No.1 People's Hospital, Xining, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Huang</LastName>
            <ForeName>Zhenxing</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Nephrology, Xining No.1 People's Hospital, Xining, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zou</LastName>
            <ForeName>Dongmei</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Endocrinology, Xining No.1 People's Hospital, Xining, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Junbin</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Nephrology, Xining No.1 People's Hospital, Xining, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Feng</LastName>
            <ForeName>Ping</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Endocrinology, Xining No.1 People's Hospital, Xining, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Ren Fail</MedlineTA>
        <NlmUniqueID>8701128</NlmUniqueID>
        <ISSNLinking>0886-022X</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D015820">Cadherins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C580643">MIRN122 microRNA, rat</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D035683">MicroRNAs</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D051902">Smad5 Protein</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C497799">Smad5 protein, rat</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D053773">Transforming Growth Factor beta1</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D014746">Vimentin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D051176">beta Catenin</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015820" MajorTopicYN="N">Cadherins</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058750" MajorTopicYN="N">Epithelial-Mesenchymal Transition</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017404" MajorTopicYN="N">In Situ Hybridization, Fluorescence</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D035683" MajorTopicYN="N">MicroRNAs</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D023421" MajorTopicYN="N">Models, Animal</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010530" MajorTopicYN="N">Peritoneal Dialysis</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D056627" MajorTopicYN="N">Peritoneal Fibrosis</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017207" MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051902" MajorTopicYN="N">Smad5 Protein</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053773" MajorTopicYN="N">Transforming Growth Factor beta1</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014746" MajorTopicYN="N">Vimentin</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D060449" MajorTopicYN="N">Wnt Signaling Pathway</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051176" MajorTopicYN="N">beta Catenin</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">MiR-122-5p</Keyword>
        <Keyword MajorTopicYN="N">Peritoneal fibrosis</Keyword>
        <Keyword MajorTopicYN="N">Smad5</Keyword>
        <Keyword MajorTopicYN="N">Wnt/β-catenin</Keyword>
        <Keyword MajorTopicYN="N">epithelial–mesenchymal transition (EMT)</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare that there are no conflicts of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>16</Day>
          <Hour>8</Hour>
          <Minute>42</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>17</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>8</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35170385</ArticleId>
        <ArticleId IdType="pmc">PMC8856067</ArticleId>
        <ArticleId IdType="doi">10.1080/0886022X.2022.2030360</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Kumar VA, Sidell MA, Jones JP, et al. . 
Survival of propensity matched incident peritoneal and hemodialysis patients in a United States health care system. Kidney Int. 2014;86(5):1016–1022.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24988066</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jain AK, Blake P, Cordy P, et al. . 
Global trends in rates of peritoneal dialysis. J Am Soc Nephrol. 2012;23(3):533–544.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3294313</ArticleId>
            <ArticleId IdType="pubmed">22302194</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Williams JD, Craig KJ, Topley N, et al. . 
Morphologic changes in the peritoneal membrane of patients with renal disease. J Am Soc Nephrol. 2002;13(2):470–479.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11805177</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aroeira LS, Aguilera A, Sánchez-Tomero JA, et al. . 
Epithelial to mesenchymal transition and peritoneal membrane failure in peritoneal dialysis patients: pathologic significance and potential therapeutic interventions. J Am Soc Nephrol. 2007;18(7):2004–2013.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17568021</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang J, Wang L, Xu L, et al. . 
Targeting src attenuates peritoneal fibrosis and inhibits the epithelial to mesenchymal transition. Oncotarget. 2017;8(48):83872–83889.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5663561</ArticleId>
            <ArticleId IdType="pubmed">29137389</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Morishita Y, Ookawara S, Hirahara I, et al. . 
HIF-1α mediates hypoxia-induced epithelial-mesenchymal transition in peritoneal mesothelial cells. Ren Fail. 2016;38(2):282–289.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26707495</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yao L, Ye Y, Mao H, et al. . 
MicroRNA-124 regulates the expression of MEKK3 in the inflammatory pathogenesis of Parkinson’s disease. J Neuroinflammation. 2018;15(1):13.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5767033</ArticleId>
            <ArticleId IdType="pubmed">29329581</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hu J, Shan Z, Hu K, et al. . 
Feng Y: miRNA-223 inhibits epithelial-mesenchymal transition in gastric carcinoma cells via Sp1. Int J Oncol. 2016;49(1):325–335.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27212195</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jaca A, Govender P, Locketz M, et al. . 
The role of miRNA-21 and epithelial mesenchymal transition (EMT) process in colorectal cancer. J Clin Pathol. 2017;70(4):331–356.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27672217</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Domingues C, Serambeque BP, Laranjo Cândido MS, et al. . 
Epithelial-mesenchymal transition and microRNAs: challenges and future perspectives in oral cancer. Head Neck. 2018;40(10):2304–2313.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30120853</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Morishita Y, Yoshizawa H, Watanabe M, et al. . 
MicroRNA expression profiling in peritoneal fibrosis. Trans Res. 2016;169:47–66.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26616819</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lin F, Wu X, Zhang H, et al. . 
A microrna screen to identify regulators of peritoneal fibrosis in a rat model of peritoneal dialysis. BMC Nephrol. 2015;16:48.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4546227</ArticleId>
            <ArticleId IdType="pubmed">25884636</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li X, Liu H, Sun L, et al. . 
MicroRNA-302c modulates peritoneal dialysis-associated fibrosis by targeting connective tissue growth factor. J Cell Mol Med. 2019;23(4):2372–2383.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6433681</ArticleId>
            <ArticleId IdType="pubmed">30693641</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Szeto CC, Chow KM, Kwan BC, et al. . 
Peritoneal dialysis effluent miR-21 and miR-589 levels correlate with longitudinal change in peritoneal transport characteristics. Clin Chim Acta. 2017;464:106–112.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27867039</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Duan Y, Dong Y, Dang R, et al. . 
MiR-122 inhibits epithelial mesenchymal transition by regulating P4HA1 in ovarian cancer cells. Cell Biol Int. 2018;42(11):1564–1574.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30136751</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Z, Wang X.. 
miR-122-5p promotes aggression and epithelial-mesenchymal transition in triple-negative breast cancer by suppressing charged multivesicular body protein 3 through mitogen-activated protein kinase signaling. J Cell Physiol. 2020;235(3):2825–2835.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31541468</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou Q, Bajo MA, Del Peso G, et al. . 
Preventing peritoneal membrane fibrosis in peritoneal dialysis patients. Kidney Int. 2016;90(3):515–524.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27282936</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Krediet RT.
Ultrafiltration failure is a reflection of peritoneal alterations in patients treated with peritoneal dialysis. Front Physiol. 2018;9:1815.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6306483</ArticleId>
            <ArticleId IdType="pubmed">30618825</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yanai K, Ishii H, Aomatsu A, et al. . 
MicroRNAs in peritoneal fibrosis: a systematic review. Discov Med. 2018;26(145):271–280.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30695676</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Calvopina DA, Chatfield MD, Weis A, et al. . 
MicroRNA sequencing identifies a serum MicroRNA panel, which combined with aspartate aminotransferase to platelet ratio index can detect and monitor liver disease in pediatric cystic fibrosis. Hepatology. 2018;68(6):2301–2316.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30014495</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim KK, Sheppard D, Chapman HA.. 
TGF-β1 signaling and tissue fibrosis. Cold Spring Harb Perspect Biol. 2018;10(4):a022293.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5880172</ArticleId>
            <ArticleId IdType="pubmed">28432134</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lepistö J, Peltonen J, Vähä-Kreula M, et al. . 
Platelet-derived growth factor isoforms PDGF-AA, -AB and -BB exert specific effects on collagen gene expression and mitotic activity of cultured human wound fibroblasts. Biochem Biophys Res Commun. 1995;209(2):393–399.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7733905</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shin HS, Ko J.. 
Metformin ameliorates the phenotype transition of peritoneal mesothelial cells and peritoneal fibrosis via a modulation of oxidative stress. Sci Rep. 2017;7(1):5690.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5515908</ArticleId>
            <ArticleId IdType="pubmed">28720775</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ji S, Deng H, Jin W, et al. . 
Beta-catenin participates in dialysate-induced peritoneal fibrosis via enhanced peritoneal cell epithelial-to-mesenchymal transition. FEBS Open Bio. 2017;7(2):265–273.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5292666</ArticleId>
            <ArticleId IdType="pubmed">28174691</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sung SA, Kim DH, Oh KH, et al. . 
The role of cathepsin B in peritoneal fibrosis due to peritoneal dialysis. Int J Nephrol. 2019;2019:4150656.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6878782</ArticleId>
            <ArticleId IdType="pubmed">31815017</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang AH, Chen JY, Lin JK.. 
Myofibroblastic conversion of mesothelial cells. Kidney Int. 2003;63(4):1530–1539.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12631370</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang CY, Xiao X, Bayer A, et al. . 
Ablation of hepatocyte Smad1, Smad5, and Smad8 causes severe tissue iron loading and liver fibrosis in mice. Hepatology. 2019;70(6):1986–2002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6874904</ArticleId>
            <ArticleId IdType="pubmed">31127639</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ishikawa K, Sreekumar PG, Spee C, et al. . 
αB-Crystallin regulates subretinal fibrosis by modulation of Epithelial-Mesenchymal transition. Am J Pathol. 2016;186(4):859–873.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4822331</ArticleId>
            <ArticleId IdType="pubmed">26878210</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>MacDonald BT, Tamai K, He X.. 
Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev Cell. 2009;17(1):9–26.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2861485</ArticleId>
            <ArticleId IdType="pubmed">19619488</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Steinhart Z, Angers S.. 
Wnt signaling in development and tissue homeostasis. 2018;145(11):dev146589.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29884654</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clevers H, Nusse R.. 
Wnt/β-catenin signaling and disease. Cell. 2012;149(6):1192–1205.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22682243</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clevers H.
Wnt/beta-catenin signaling in development and disease. Cell. 2006;127(3):469–480.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17081971</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guo Y, Xiao L, Sun L, et al. . 
Wnt/beta-catenin signaling: a promising new target for fibrosis diseases. Physiol Res. 2012;61(4):337–346.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22670697</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Surendran K, Schiavi S, Hruska KA.. 
Wnt-dependent beta-catenin signaling is activated after unilateral ureteral obstruction, and recombinant secreted frizzled-related protein 4 alters the progression of renal fibrosis. J Am Soc Nephrol. 2005;16(8):2373–2384.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15944336</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guo Y, Sun L, Xiao L, et al. . 
Aberrant wnt/Beta-Catenin pathway activation in Dialysate-Induced peritoneal fibrosis. Front Pharmacol. 2017;8:774.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5670149</ArticleId>
            <ArticleId IdType="pubmed">29163160</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu M, Shi J, Sheng M, et al. . 
Astragalus inhibits epithelial-to-Mesenchymal transition of peritoneal mesothelial cells by down-Regulating β-Catenin. Cell Physiol Biochem. 2018;51(6):2794–2813.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30562743</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">35170385</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>07</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>07</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1525-6049</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>44</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Dec</Month>
            </PubDate>
          </JournalIssue>
          <Title>Renal failure</Title>
          <ISOAbbreviation>Ren Fail</ISOAbbreviation>
        </Journal>
        <ArticleTitle>MiR-122-5p promotes peritoneal fibrosis in a rat model of peritoneal dialysis by targeting Smad5 to activate Wnt/β-catenin pathway.</ArticleTitle>
        <Pagination>
          <StartPage>191</StartPage>
          <EndPage>203</EndPage>
          <MedlinePgn>191-203</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1080/0886022X.2022.2030360</ELocationID>
        <Abstract>
          <AbstractText>Peritoneal fibrosis (PF) is the main reason leading to declining efficiency and ultrafiltration failure of peritoneum, which restricts the application of peritoneal dialysis (PD). We aimed to investigate the effects and mechanisms of miR-122-5p on the PF. Sprague-Dawley (SD) rats were infused with glucose-based standard PD fluid to establish PF model. HE staining was performed to evaluate the extent of PF. Real-time fluorescence quantitative polymerase chain reaction (RT-qPCR) and fluorescence <i>in situ</i> hybridization (FISH) were performed to measure the expression level of miR-122-5p. Western blot was used to test the expression of transforming growth factor (TGF)-β1, platelet-derived growth factor (PDGF)-A, Fibronectin 1 (FN1), extracellular matrix protein 1 (ECM1), Smad5, α-smooth muscle actin (SMA), collagen type 1(COL-1), Vimentin, E-Cadherin, Wnt1, β-catenin, p-β-catenin, c-Myc, c-Jun, and Cyclin D1. Immunohistochemistry (IHC) staining was used to detect type I collagen alpha 1 (Col1α1), α-SMA, and E-Cadherin expression. We found PF was glucose concentration-dependently enhanced in peritoneum of PD rat. The PD rats showed increased miR-122-5p and decreased Smad5 expression. MiR-122-5p silencing improved PF and epithelial-mesenchymal transition (EMT) process in PD rats. MiR-122-5p silencing attenuated the activity of the Wnt/β-catenin signaling pathway. Importantly, dual-luciferase reporter assay showed Smad5 was a target gene of miR-122-5p. Smad5 overexpression significantly reversed the increases of PF and EMT progression induced by miR-122-5p overexpression. Moreover, miR-122-5p mimic activated Wnt/β-catenin activity, which was blocked by Smad5 overexpression. Overall, present results demonstrated that miR-122-5p overexpression showed a deterioration effect on PD-related PF by targeting Smad5 to activate Wnt/β-catenin pathway.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Yirong</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Nephrology, Xining No.1 People's Hospital, Xining, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ma</LastName>
            <ForeName>Zhihong</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Nephrology, Xining No.1 People's Hospital, Xining, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Huang</LastName>
            <ForeName>Zhenxing</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Nephrology, Xining No.1 People's Hospital, Xining, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zou</LastName>
            <ForeName>Dongmei</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Endocrinology, Xining No.1 People's Hospital, Xining, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Junbin</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Nephrology, Xining No.1 People's Hospital, Xining, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Feng</LastName>
            <ForeName>Ping</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Endocrinology, Xining No.1 People's Hospital, Xining, PR China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Ren Fail</MedlineTA>
        <NlmUniqueID>8701128</NlmUniqueID>
        <ISSNLinking>0886-022X</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D015820">Cadherins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C580643">MIRN122 microRNA, rat</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D035683">MicroRNAs</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D051902">Smad5 Protein</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C497799">Smad5 protein, rat</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D053773">Transforming Growth Factor beta1</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D014746">Vimentin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D051176">beta Catenin</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015820" MajorTopicYN="N">Cadherins</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058750" MajorTopicYN="N">Epithelial-Mesenchymal Transition</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017404" MajorTopicYN="N">In Situ Hybridization, Fluorescence</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D035683" MajorTopicYN="N">MicroRNAs</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D023421" MajorTopicYN="N">Models, Animal</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010530" MajorTopicYN="N">Peritoneal Dialysis</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D056627" MajorTopicYN="N">Peritoneal Fibrosis</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017207" MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051902" MajorTopicYN="N">Smad5 Protein</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053773" MajorTopicYN="N">Transforming Growth Factor beta1</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014746" MajorTopicYN="N">Vimentin</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D060449" MajorTopicYN="N">Wnt Signaling Pathway</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051176" MajorTopicYN="N">beta Catenin</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">MiR-122-5p</Keyword>
        <Keyword MajorTopicYN="N">Peritoneal fibrosis</Keyword>
        <Keyword MajorTopicYN="N">Smad5</Keyword>
        <Keyword MajorTopicYN="N">Wnt/β-catenin</Keyword>
        <Keyword MajorTopicYN="N">epithelial–mesenchymal transition (EMT)</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare that there are no conflicts of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>16</Day>
          <Hour>8</Hour>
          <Minute>42</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>17</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>8</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35170385</ArticleId>
        <ArticleId IdType="pmc">PMC8856067</ArticleId>
        <ArticleId IdType="doi">10.1080/0886022X.2022.2030360</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Kumar VA, Sidell MA, Jones JP, et al. . 
Survival of propensity matched incident peritoneal and hemodialysis patients in a United States health care system. Kidney Int. 2014;86(5):1016–1022.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24988066</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jain AK, Blake P, Cordy P, et al. . 
Global trends in rates of peritoneal dialysis. J Am Soc Nephrol. 2012;23(3):533–544.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3294313</ArticleId>
            <ArticleId IdType="pubmed">22302194</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Williams JD, Craig KJ, Topley N, et al. . 
Morphologic changes in the peritoneal membrane of patients with renal disease. J Am Soc Nephrol. 2002;13(2):470–479.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11805177</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aroeira LS, Aguilera A, Sánchez-Tomero JA, et al. . 
Epithelial to mesenchymal transition and peritoneal membrane failure in peritoneal dialysis patients: pathologic significance and potential therapeutic interventions. J Am Soc Nephrol. 2007;18(7):2004–2013.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17568021</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang J, Wang L, Xu L, et al. . 
Targeting src attenuates peritoneal fibrosis and inhibits the epithelial to mesenchymal transition. Oncotarget. 2017;8(48):83872–83889.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5663561</ArticleId>
            <ArticleId IdType="pubmed">29137389</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Morishita Y, Ookawara S, Hirahara I, et al. . 
HIF-1α mediates hypoxia-induced epithelial-mesenchymal transition in peritoneal mesothelial cells. Ren Fail. 2016;38(2):282–289.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26707495</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yao L, Ye Y, Mao H, et al. . 
MicroRNA-124 regulates the expression of MEKK3 in the inflammatory pathogenesis of Parkinson’s disease. J Neuroinflammation. 2018;15(1):13.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5767033</ArticleId>
            <ArticleId IdType="pubmed">29329581</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hu J, Shan Z, Hu K, et al. . 
Feng Y: miRNA-223 inhibits epithelial-mesenchymal transition in gastric carcinoma cells via Sp1. Int J Oncol. 2016;49(1):325–335.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27212195</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jaca A, Govender P, Locketz M, et al. . 
The role of miRNA-21 and epithelial mesenchymal transition (EMT) process in colorectal cancer. J Clin Pathol. 2017;70(4):331–356.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27672217</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Domingues C, Serambeque BP, Laranjo Cândido MS, et al. . 
Epithelial-mesenchymal transition and microRNAs: challenges and future perspectives in oral cancer. Head Neck. 2018;40(10):2304–2313.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30120853</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Morishita Y, Yoshizawa H, Watanabe M, et al. . 
MicroRNA expression profiling in peritoneal fibrosis. Trans Res. 2016;169:47–66.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26616819</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lin F, Wu X, Zhang H, et al. . 
A microrna screen to identify regulators of peritoneal fibrosis in a rat model of peritoneal dialysis. BMC Nephrol. 2015;16:48.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4546227</ArticleId>
            <ArticleId IdType="pubmed">25884636</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li X, Liu H, Sun L, et al. . 
MicroRNA-302c modulates peritoneal dialysis-associated fibrosis by targeting connective tissue growth factor. J Cell Mol Med. 2019;23(4):2372–2383.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6433681</ArticleId>
            <ArticleId IdType="pubmed">30693641</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Szeto CC, Chow KM, Kwan BC, et al. . 
Peritoneal dialysis effluent miR-21 and miR-589 levels correlate with longitudinal change in peritoneal transport characteristics. Clin Chim Acta. 2017;464:106–112.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27867039</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Duan Y, Dong Y, Dang R, et al. . 
MiR-122 inhibits epithelial mesenchymal transition by regulating P4HA1 in ovarian cancer cells. Cell Biol Int. 2018;42(11):1564–1574.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30136751</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Z, Wang X.. 
miR-122-5p promotes aggression and epithelial-mesenchymal transition in triple-negative breast cancer by suppressing charged multivesicular body protein 3 through mitogen-activated protein kinase signaling. J Cell Physiol. 2020;235(3):2825–2835.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31541468</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou Q, Bajo MA, Del Peso G, et al. . 
Preventing peritoneal membrane fibrosis in peritoneal dialysis patients. Kidney Int. 2016;90(3):515–524.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27282936</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Krediet RT.
Ultrafiltration failure is a reflection of peritoneal alterations in patients treated with peritoneal dialysis. Front Physiol. 2018;9:1815.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6306483</ArticleId>
            <ArticleId IdType="pubmed">30618825</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yanai K, Ishii H, Aomatsu A, et al. . 
MicroRNAs in peritoneal fibrosis: a systematic review. Discov Med. 2018;26(145):271–280.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30695676</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Calvopina DA, Chatfield MD, Weis A, et al. . 
MicroRNA sequencing identifies a serum MicroRNA panel, which combined with aspartate aminotransferase to platelet ratio index can detect and monitor liver disease in pediatric cystic fibrosis. Hepatology. 2018;68(6):2301–2316.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30014495</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim KK, Sheppard D, Chapman HA.. 
TGF-β1 signaling and tissue fibrosis. Cold Spring Harb Perspect Biol. 2018;10(4):a022293.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5880172</ArticleId>
            <ArticleId IdType="pubmed">28432134</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lepistö J, Peltonen J, Vähä-Kreula M, et al. . 
Platelet-derived growth factor isoforms PDGF-AA, -AB and -BB exert specific effects on collagen gene expression and mitotic activity of cultured human wound fibroblasts. Biochem Biophys Res Commun. 1995;209(2):393–399.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7733905</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shin HS, Ko J.. 
Metformin ameliorates the phenotype transition of peritoneal mesothelial cells and peritoneal fibrosis via a modulation of oxidative stress. Sci Rep. 2017;7(1):5690.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5515908</ArticleId>
            <ArticleId IdType="pubmed">28720775</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ji S, Deng H, Jin W, et al. . 
Beta-catenin participates in dialysate-induced peritoneal fibrosis via enhanced peritoneal cell epithelial-to-mesenchymal transition. FEBS Open Bio. 2017;7(2):265–273.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5292666</ArticleId>
            <ArticleId IdType="pubmed">28174691</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sung SA, Kim DH, Oh KH, et al. . 
The role of cathepsin B in peritoneal fibrosis due to peritoneal dialysis. Int J Nephrol. 2019;2019:4150656.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6878782</ArticleId>
            <ArticleId IdType="pubmed">31815017</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang AH, Chen JY, Lin JK.. 
Myofibroblastic conversion of mesothelial cells. Kidney Int. 2003;63(4):1530–1539.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12631370</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang CY, Xiao X, Bayer A, et al. . 
Ablation of hepatocyte Smad1, Smad5, and Smad8 causes severe tissue iron loading and liver fibrosis in mice. Hepatology. 2019;70(6):1986–2002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6874904</ArticleId>
            <ArticleId IdType="pubmed">31127639</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ishikawa K, Sreekumar PG, Spee C, et al. . 
αB-Crystallin regulates subretinal fibrosis by modulation of Epithelial-Mesenchymal transition. Am J Pathol. 2016;186(4):859–873.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4822331</ArticleId>
            <ArticleId IdType="pubmed">26878210</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>MacDonald BT, Tamai K, He X.. 
Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev Cell. 2009;17(1):9–26.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2861485</ArticleId>
            <ArticleId IdType="pubmed">19619488</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Steinhart Z, Angers S.. 
Wnt signaling in development and tissue homeostasis. 2018;145(11):dev146589.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29884654</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clevers H, Nusse R.. 
Wnt/β-catenin signaling and disease. Cell. 2012;149(6):1192–1205.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22682243</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clevers H.
Wnt/beta-catenin signaling in development and disease. Cell. 2006;127(3):469–480.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17081971</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guo Y, Xiao L, Sun L, et al. . 
Wnt/beta-catenin signaling: a promising new target for fibrosis diseases. Physiol Res. 2012;61(4):337–346.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22670697</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Surendran K, Schiavi S, Hruska KA.. 
Wnt-dependent beta-catenin signaling is activated after unilateral ureteral obstruction, and recombinant secreted frizzled-related protein 4 alters the progression of renal fibrosis. J Am Soc Nephrol. 2005;16(8):2373–2384.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15944336</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guo Y, Sun L, Xiao L, et al. . 
Aberrant wnt/Beta-Catenin pathway activation in Dialysate-Induced peritoneal fibrosis. Front Pharmacol. 2017;8:774.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5670149</ArticleId>
            <ArticleId IdType="pubmed">29163160</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu M, Shi J, Sheng M, et al. . 
Astragalus inhibits epithelial-to-Mesenchymal transition of peritoneal mesothelial cells by down-Regulating β-Catenin. Cell Physiol Biochem. 2018;51(6):2794–2813.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30562743</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
